| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update JS Smolen, RBM Landewé, SA Bergstra, A Kerschbaumer, A Sepriano, ... Annals of the rheumatic diseases 82 (1), 3-18, 2023 | 495 | 2023 |
| Global epidemiology of rheumatoid arthritis A Finckh, B Gilbert, B Hodkinson, SC Bae, R Thomas, KD Deane, ... Nature Reviews Rheumatology 18 (10), 591-602, 2022 | 248 | 2022 |
| Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study N Madelon, K Lauper, G Breville, I Sabater Royo, R Goldstein, DO Andrey, ... Clinical Infectious Diseases, 2021 | 115* | 2021 |
| Cardiovascular risk in patients with rheumatoid arthritis K Lauper, C Gabay Seminars in immunopathology 39 (4), 447-459, 2017 | 72 | 2017 |
| Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients … K Lauper, DC Nordström, K Pavelka, MV Hernández, TK Kvien, ... Annals of the rheumatic diseases 77 (9), 1276-1282, 2018 | 70 | 2018 |
| The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries DS Courvoisier, K Chatzidionysiou, D Mongin, K Lauper, X Mariette, ... Rheumatology 60 (2), 820-828, 2021 | 66 | 2021 |
| Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis K Lauper, DS Courvoisier, P Chevallier, A Finckh, C Gabay Arthritis care & research 70 (12), 1756-1763, 2018 | 64 | 2018 |
| Omicron-specific cytotoxic T-cell responses after a third dose of mRNA COVID-19 vaccine among patients with multiple sclerosis treated with ocrelizumab N Madelon, N Heikkilä, IS Royo, P Fontannaz, G Breville, K Lauper, ... JAMA neurology 79 (4), 399-404, 2022 | 63 | 2022 |
| 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases GE Fragoulis, E Nikiphorou, M Dey, SS Zhao, DS Courvoisier, L Arnaud, ... Annals of the rheumatic diseases 82 (6), 742-753, 2023 | 60 | 2023 |
| Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’collaboration K Lauper, M Iudici, D Mongin, SA Bergstra, D Choquette, C Codreanu, ... Annals of the rheumatic diseases 81 (10), 1358-1366, 2022 | 55 | 2022 |
| The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus R Giacomelli, A Afeltra, E Bartoloni, O Berardicurti, M Bombardieri, ... Autoimmunity Reviews, 102738, 2020 | 39 | 2020 |
| One‐year persistent symptoms and functional impairment in SARS‐CoV‐2 positive and negative individuals M Nehme, O Braillard, F Chappuis, DS Courvoisier, L Kaiser, PM Soccal, ... Journal of Internal Medicine, 2022 | 32 | 2022 |
| The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis D Alpizar-Rodriguez, L Brulhart, RB Mueller, B Möller, J Dudler, A Ciurea, ... Clinical rheumatology 36 (3), 677-682, 2017 | 31 | 2017 |
| Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique? D Mongin, K Lauper, C Turesson, ML Hetland, EK Kristianslund, TK Kvien, ... RMD open 5 (2), e000994, 2019 | 27 | 2019 |
| Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort … K Lauper, D Mongin, F Iannone, EK Kristianslund, TK Kvien, ... Seminars in arthritis and rheumatism 50 (1), 17-24, 2020 | 26 | 2020 |
| Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries K Lauper, D Mongin, F Iannone, EK Kristianslund, TK Kvien, D Nordström, ... RMD open 4 (2), e000809, 2018 | 22 | 2018 |
| Prevalence of post-COVID condition 12 weeks after Omicron infection compared to negative controls and association with vaccination status M Nehme, P Vetter, F Chappuis, L Kaiser, I Guessous, O Braillard, F Assal, ... Clinical Infectious Diseases, 2022 | 21* | 2022 |
| EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology DS Courvoisier, K Lauper, J Kedra, M De Wit, B Fautrel, T Frisell, ... Annals of the rheumatic diseases 81 (6), 780-785, 2022 | 18* | 2022 |
| Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis BTP Gilbert, C Lamacchia, D Mongin, K Lauper, E Trunk, O Studer, ... BMJ open 11 (7), e048409, 2021 | 18 | 2021 |
| Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients N Madelon, N Heikkilä, IS Royo, P Fontannaz, G Breville, K Lauper, ... Medrxiv, 2021 | 17 | 2021 |
Axel FinckhGeneva University ORHUG OR CHUV OR BrighamBestätigte E-Mail-Adresse bei hcuge.ch
